-
"Biomarkers can play a key role in improving diagnosis and disease management of heart failure. "
biospectrumasia
November 15, 2018
Recently, Priyanka Bajpai from BioSpectrum Asia spoke to Dr Antoni Bayes-Genis on the need to staying healthy and the future of NT-proBNP as a cardiac biomarker.
-
AstraZeneca sells European rights for heart failure treatment for $210M
biospectrumasia
July 25, 2018
Cheplapharm would pay AstraZeneca $200m on completion of the agreement, expected to be finalised in the third quarter of 2018, plus a time-bound payment of $10m and sales-contingent milestones.
-
AstraZeneca sells Atacand rights to Cheplapharm
pharmatimes
July 25, 2018
AstraZeneca is selling rights to its heart failure and hypertension brand Atacand in Europe, in a move that it says will expand its commercial potential in 28 countries.
-
Orion takes repurposed heart failure drug into phase 3 for ALS
fiercebiotech
July 09, 2018
Finnish drugmaker Orion Pharma is pressing ahead with a pivotal trial for its amyotrophic lateral sclerosis drug ODM-109, despite mixed results in a phase 2 trial.
-
Bayer expands Broad Institute partnership to focus on heart failure
pharmafile
July 06, 2018
The PCL will be situated at the Massachusetts-based biomedical and genomic research centre. The cardiology lab will leverage new tools and approaches in an effort to gain greater insight into the causes of heart failure while working towards developing me
-
Phase III CardiAMP Heart Failure Trial Featured in American Heart Journal
biospace
April 10, 2018
BioCardia?, Inc., [OTC: BCDA] a leader in cardiovascular regenerative medicine, today announced the publication of the Phase III CardiAMP Heart Failure Trial design paper in the American Heart Journal.
-
Aspirin lowers risk of death for patients with diabetes and heart failure
europeanpharmaceuticalreview
March 01, 2018
Researchers assess aspirin as a preventive measure for patients who have both diabetes and heart failure…
-
New Novartis Entresto? real world evidence data shows beneficial impact on quality of life in people
worldpharmanews
November 14, 2017
Novartis has announced new results from a real-world database study of patients in Germany prescribed Entresto? (sacubitril/valsartan) for heart failure with reduced ejection fraction (HFrEF).
-
After a slow start, Novartis finally gains market traction with heart drug Entresto
fiercepharma
August 16, 2017
Novartis CEO Joe Jimenez told investors during a recent earnings call that heart failure drug Entresto is winning over insurers.
-
Audit shows drop in hospital heart failure deaths
pharmatimes
August 15, 2017
The latest national heart failure audit has found a significant downturn in the mortality rate among heart failure patients admitted to hospital over the past year, but says the number of ...
ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
Pharma Sources Insight January 2025
